+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
mRNA Therapeutics Market - Global Forecast 2026-2032- Product Image
mRNA Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

mRNA Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 185 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5666329
UP TO OFF until Dec 31st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The mRNA Therapeutics Market is projected to reach USD 12.58 Billion in 2026. It is expected to continue growing at a CAGR of 13.23%, reaching USD 27.05 Billion by 2032.

mRNA therapeutics have moved from a specialist platform into a central pillar of modern biopharmaceutical innovation, supported by advances in nucleoside modification, lipid nanoparticle delivery, scalable in vitro transcription, and improved analytical characterization. The field spans prophylactic vaccines, cancer immunotherapy, protein replacement, gene editing support, regenerative medicine, and treatments for rare and infectious diseases. Its strategic value lies in programmability: once a target antigen or protein sequence is defined, developers can design, manufacture, and iterate candidates faster than many conventional biologics. Regulatory experience gained from authorized mRNA vaccines has strengthened expectations around quality controls, pharmacovigilance, cold-chain management, and benefit-risk assessment. As stakeholders seek platforms that can respond to emerging pathogens, personalized oncology needs, and previously undruggable targets, mRNA therapeutics are increasingly positioned as a high-impact modality within precision medicine and next-generation biologics.

Transformative Shifts in the mRNA Therapeutics Landscape

The mRNA therapeutics landscape is being reshaped by improvements in delivery systems, manufacturing flexibility, and clinical application diversity. Lipid nanoparticles remain the most established delivery vehicle, but research is expanding into targeted formulations, polymeric carriers, and tissue-selective delivery approaches to improve tolerability and enable administration beyond the liver and immune system. Self-amplifying RNA, circular RNA, and optimized untranslated regions are gaining attention for their potential to extend expression, reduce dose requirements, and improve therapeutic durability. Manufacturing is also shifting toward modular, automated, and geographically distributed capacity, helping reduce dependency on centralized production and supporting faster outbreak response. Clinically, the sector is broadening from pandemic-driven vaccines toward individualized cancer vaccines, respiratory virus combinations, autoimmune modulation, rare disease protein expression, and in vivo gene editing enablement. These shifts are creating a more complex but more resilient ecosystem in which platform design, delivery precision, regulatory readiness, and supply-chain reliability are becoming decisive competitive factors.

Cumulative Impact of Artificial Intelligence on mRNA Therapeutics

Artificial intelligence is accelerating mRNA therapeutics by improving target discovery, sequence design, formulation optimization, clinical trial planning, and post-market safety monitoring. Machine learning models support antigen selection, epitope prediction, codon optimization, secondary structure assessment, and immunogenicity risk evaluation, helping researchers refine candidates before laboratory validation. In delivery research, AI-enabled modeling can evaluate lipid composition, particle stability, biodistribution signals, and manufacturability parameters across large experimental datasets. In clinical development, data science tools improve patient stratification, biomarker selection, site activation planning, and adaptive trial design, particularly in oncology and rare diseases where patient populations are heterogeneous. AI also strengthens pharmacovigilance by detecting adverse event patterns across real-world data, registries, and safety reports. While these capabilities can reduce experimental friction, the cumulative impact depends on transparent model validation, high-quality biological datasets, regulatory-grade documentation, and safeguards against bias. The strongest outcomes are expected where AI is integrated with wet-lab testing, clinical evidence generation, and robust quality-by-design practices.

Key Regional Insights for mRNA Therapeutics

Regional dynamics in mRNA therapeutics reflect differences in scientific infrastructure, regulatory maturity, manufacturing capacity, public health priorities, and investment in biotechnology. Asia-Pacific is strengthening its role through expanding vaccine manufacturing, growing clinical research networks, and national initiatives in China, Japan, South Korea, Australia, India, and ASEAN markets that prioritize pandemic preparedness and biopharmaceutical self-reliance. North America remains highly active due to advanced academic research, mature regulatory pathways, deep clinical trial infrastructure, and strong demand for oncology, infectious disease, and rare disease innovation. Latin America is increasingly relevant for vaccine access, local fill-finish capabilities, infectious disease surveillance, and public-private collaboration, with Brazil and Mexico serving as important anchors for regional clinical development and manufacturing partnerships. Europe benefits from coordinated regulatory expertise, strong translational science, and cross-border research programs, while emphasizing quality, safety monitoring, and resilient supply chains. The Middle East is building biotechnology capabilities through healthcare modernization, sovereign investment, and life sciences infrastructure, particularly in Gulf economies seeking regional manufacturing and clinical research capabilities. Africa’s mRNA therapeutics opportunity is closely tied to vaccine equity, technology transfer, workforce development, disease surveillance, and localized production capacity, supported by growing recognition that regional manufacturing can improve outbreak response and long-term health security.

Key Group Insights for mRNA Therapeutics

Group-level dynamics show how policy alignment, trade relationships, health security priorities, and scientific collaboration influence mRNA therapeutics adoption and development. ASEAN countries are focusing on regional health resilience, regulatory cooperation, vaccine access, and biomanufacturing partnerships that can support faster response to infectious disease threats across Southeast Asia. GCC members are advancing healthcare diversification through investment in biotechnology parks, precision medicine programs, clinical research capacity, and local manufacturing ambitions, positioning the region as an emerging hub for advanced therapeutics. The European Union provides a highly structured environment for mRNA research through harmonized regulatory oversight, cross-border funding mechanisms, pharmacovigilance systems, and coordinated public health frameworks. BRICS countries bring substantial relevance through large patient populations, expanding scientific talent, public health manufacturing experience, and policy emphasis on domestic biopharmaceutical capability. G7 countries continue to shape mRNA therapeutics through regulatory leadership, advanced R&D ecosystems, global health financing, and preparedness strategies focused on rapid vaccine and therapeutic response. NATO-aligned countries increasingly view biotechnology supply chains, medical countermeasures, and pandemic response capacity as part of broader health security and resilience planning, reinforcing the strategic importance of mRNA platforms in national preparedness frameworks.

Key Country Insights for mRNA Therapeutics

Country-level insights highlight the diverse pathways shaping mRNA therapeutics development and access. The United States leads in translational research depth, clinical trial density, regulatory experience, and advanced manufacturing know-how, with strong activity across infectious disease, oncology, rare diseases, and gene editing applications. Canada contributes through academic excellence, public health preparedness, and investments in domestic biomanufacturing capacity. Mexico is gaining importance through clinical trial participation, regional manufacturing relevance, and proximity to North American supply chains. Brazil plays a major role in Latin America through public health institutions, vaccine production experience, and infectious disease research capacity. The United Kingdom combines genomic medicine leadership, clinical research networks, and regulatory agility that support advanced therapeutic development. Germany is a major European biotechnology center with strengths in RNA science, manufacturing engineering, and translational medicine, while France emphasizes biomedical research, vaccine policy, and healthcare innovation. Russia maintains scientific capacity in immunology and vaccine research, although international collaboration and technology access are influenced by geopolitical constraints. Italy and Spain contribute through clinical research networks, hospital-based trial infrastructure, and growing interest in oncology and infectious disease applications. China is rapidly advancing mRNA therapeutics through domestic platform development, manufacturing scale-up, and large biomedical research programs. India is important for vaccine manufacturing expertise, cost-efficient production capabilities, and expanding biotechnology policy support. Japan brings strengths in precision medicine, regulatory science, and high-quality clinical research, while Australia supports early-stage clinical development through strong research institutions and an efficient trial environment. South Korea is investing heavily in biomanufacturing, vaccine sovereignty, and advanced therapy infrastructure, strengthening its position in the Asia-Pacific mRNA ecosystem.

Actionable Recommendations for mRNA Therapeutics Leaders

Industry leaders should prioritize delivery innovation, manufacturing resilience, and evidence generation to advance mRNA therapeutics responsibly. First, invest in tissue-targeted delivery systems and formulation analytics that improve safety, tolerability, and therapeutic precision beyond vaccine applications. Second, build flexible manufacturing platforms with validated raw material sourcing, contamination controls, cold-chain alternatives, and rapid changeover capabilities. Third, integrate quality-by-design principles early, including critical quality attribute mapping, potency assays, stability testing, and comparability strategies. Fourth, use AI and automation selectively where they can be validated through reproducible experimental and clinical evidence. Fifth, strengthen regulatory engagement by aligning development plans with evolving guidance on RNA characterization, delivery systems, immunogenicity, and long-term safety monitoring. Sixth, expand clinical development models that include diverse populations, decentralized elements, biomarker-driven enrollment, and real-world evidence collection. Finally, pursue responsible technology transfer and regional partnerships that improve equitable access while protecting quality, biosafety, and supply-chain integrity.

Research Methodology

This executive summary is developed through a structured secondary research approach focused on verified, data-backed industry evidence. Inputs include peer-reviewed scientific literature, regulatory guidance and assessment documents, clinical trial registries, public health agency publications, patent and technology trend reviews, national biotechnology policy documents, and validated information from recognized healthcare and life sciences institutions. The methodology emphasizes triangulation across scientific, regulatory, and policy sources to identify recurring trends in delivery technology, clinical development, manufacturing, regional capability, and health security relevance. Qualitative analysis is used to assess strategic shifts without presenting market sizing, market share, market estimation, or forecasting. Regional, group, and country insights are synthesized from documented infrastructure, policy priorities, clinical research activity, manufacturing initiatives, and public health needs. The research process prioritizes source credibility, recency, traceability, and consistency, while avoiding unsupported claims and promotional positioning.

Conclusion

mRNA therapeutics are entering a broader and more technically sophisticated phase, moving beyond emergency vaccine response into a diversified platform for precision medicine, cancer therapy, infectious disease prevention, rare disease treatment, and gene editing enablement. The next stage of progress will depend on resolving delivery limitations, strengthening manufacturing reliability, improving stability and access, and generating rigorous clinical evidence across varied therapeutic areas. Regional and national investments in biomanufacturing, regulatory capacity, and health security are making the ecosystem more distributed, while AI and advanced analytics are improving the speed and precision of discovery and development. Stakeholders that combine scientific rigor, scalable production, transparent safety monitoring, and equitable access strategies will be best positioned to shape the future of mRNA therapeutics. As the modality matures, its long-term impact will be defined not only by speed of design but by demonstrable patient benefit, trusted quality systems, and sustainable integration into global healthcare infrastructure.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. mRNA Therapeutics Market, by Product Type
7.1. Introduction
7.2. Prophylactic mRNA Vaccines
7.2.1. Infectious Disease Vaccines
7.2.2. Pandemic Preparedness Vaccines
7.2.3. Seasonal Vaccines
7.3. Therapeutic mRNA Medicines
7.3.1. Oncology Immunotherapies
7.3.2. Protein Replacement Therapies
7.3.3. Gene Editing-Encoding Therapies
7.3.4. In Vivo Cell Programming Therapies
7.3.5. Immune Modulation Therapies
7.3.6. Regenerative And Tissue Repair Therapies
8. mRNA Therapeutics Market, by Delivery Technology
8.1. Introduction
8.2. Lipid Nanoparticle Delivery Systems
8.3. Polymer-Based Delivery Systems
8.4. Lipopolyplex Delivery Systems
8.5. Peptide-Based Delivery Systems
8.6. Viral Vector-Assisted Delivery Systems
8.7. Naked mRNA Delivery Systems
9. mRNA Therapeutics Market, by Molecule Encoding Type
9.1. Introduction
9.2. Antigen-Encoding mRNA
9.3. Cytokine-Encoding mRNA
9.4. Antibody-Encoding mRNA
9.5. Enzyme-Encoding mRNA
9.6. Growth Factor-Encoding mRNA
9.7. Gene Editing Component-Encoding mRNA
10. mRNA Therapeutics Market, by mRNA Type
10.1. Introduction
10.2. Conventional Non-Replicating mRNA
10.3. Self-Amplifying mRNA
10.4. Circular RNA Therapeutics
10.5. Trans-Amplifying mRNA
11. mRNA Therapeutics Market, by Route Of Administration
11.1. Introduction
11.2. Intramuscular Administration
11.3. Intravenous Administration
11.4. Intradermal Administration
11.5. Subcutaneous Administration
11.6. Intranasal Administration
11.7. Intratumoral Administration
12. mRNA Therapeutics Market, by Therapeutic Area
12.1. Introduction
12.2. Cardiovascular
12.3. Infectious Diseases
12.4. Oncology
12.5. Rare Diseases
12.6. Autoimmune Diseases
12.7. Neurological Disorders
12.8. Respiratory Diseases
12.9. Regenerative Medicine
13. mRNA Therapeutics Market, by End User
13.1. Introduction
13.2. Hospitals
13.3. Specialty Clinics
13.4. Academic & Research Institutes
13.5. Biotechnology Companies
13.6. Pharmaceutical Companies
13.7. Contract Research Organizations
14. mRNA Therapeutics Market, by Development Stage
14.1. Introduction
14.2. Discovery Stage
14.3. Preclinical Stage
14.4. Clinical Stage
14.4.1. Phase I
14.4.2. Phase II
14.4.3. Phase III
14.5. Commercialized Products
15. mRNA Therapeutics Market, by Region
15.1. Asia-Pacific
15.2. North America
15.3. Latin America
15.4. Europe
15.5. Middle East
15.6. Africa
16. mRNA Therapeutics Market, by Group
16.1. ASEAN
16.2. GCC
16.3. European Union
16.4. BRICS
16.5. G7
16.6. NATO
17. mRNA Therapeutics Market, by Country
17.1. United States
17.2. Canada
17.3. Mexico
17.4. Brazil
17.5. United Kingdom
17.6. Germany
17.7. France
17.8. Russia
17.9. Italy
17.10. Spain
17.11. China
17.12. India
17.13. Japan
17.14. Australia
17.15. South Korea
18. Competitive Landscape
18.1. Market Share Analysis, 2025
18.2. FPNV Positioning Matrix, 2025
18.3. Market Concentration Analysis, 2025
18.3.1. Concentration Ratio (CR)
18.3.2. Herfindahl Hirschman Index (HHI)
18.4. Recent Developments & Impact Analysis, 2025
18.5. Product Portfolio Analysis, 2025
18.6. Benchmarking Analysis, 2025
19. Company Profiles
19.1. AbbVie Inc.
19.2. Abogen Biosciences Co., Ltd.
19.3. Acuitas Therapeutics Inc.
19.4. Arcturus Therapeutics Holdings Inc.
19.5. Beam Therapeutics Inc.
19.6. BioNTech SE
19.7. CanSino Biologics Inc.
19.8. Carisma Therapeutics Inc.
19.9. Cartesian Therapeutics, Inc.
19.10. CSL Limited
19.11. CSPC Pharmaceutical Group Limited
19.12. Daiichi Sankyo Company, Limited
19.13. Eli Lilly and Company
19.14. Entos Pharmaceuticals Inc.
19.15. Esperovax, Inc.
19.16. eTheRNA immunotherapies NV
19.17. Ethris GmbH
19.18. GSK plc
19.19. HDT Bio Corp.
19.20. Intellia Therapeutics, Inc.
19.21. Kernal Biologics, Inc.
19.22. Meiji Holdings Co., Ltd.
19.23. Merck & Co., Inc.
19.24. Moderna, Inc.
19.25. Nutcracker Therapeutics, Inc.
19.26. Pfizer Inc.
19.27. Providence Therapeutics Holdings Inc.
19.28. ReCode Therapeutics, Inc.
19.29. Replicate Bioscience, Inc.
19.30. Sanofi SA
19.31. Stemirna Therapeutics Co., Ltd.
19.32. Strand Therapeutics, Inc.
19.33. Tessera Therapeutics, Inc.
19.34. Tiba Biotech LLC
19.35. Walvax Biotechnology Co., Ltd.
List of Figures
FIGURE 1. GLOBAL MRNA THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL MRNA THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL MRNA THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL MRNA THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL MRNA THERAPEUTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 9. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY MOLECULE ENCODING TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY MOLECULE ENCODING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY MRNA TYPE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY MRNA TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
FIGURE 17. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 19. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2025 VS 2032 (%)
FIGURE 21. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 23. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 25. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 27. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. GLOBAL MRNA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 29. GLOBAL MRNA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL MRNA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL MRNA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL PROPHYLACTIC MRNA VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL PROPHYLACTIC MRNA VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL PROPHYLACTIC MRNA VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL INFECTIOUS DISEASE VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL INFECTIOUS DISEASE VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL INFECTIOUS DISEASE VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL PANDEMIC PREPAREDNESS VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL PANDEMIC PREPAREDNESS VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL PANDEMIC PREPAREDNESS VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL SEASONAL VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL SEASONAL VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL SEASONAL VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL THERAPEUTIC MRNA MEDICINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL THERAPEUTIC MRNA MEDICINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL THERAPEUTIC MRNA MEDICINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL ONCOLOGY IMMUNOTHERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL ONCOLOGY IMMUNOTHERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL ONCOLOGY IMMUNOTHERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL PROTEIN REPLACEMENT THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL PROTEIN REPLACEMENT THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL PROTEIN REPLACEMENT THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL GENE EDITING-ENCODING THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL GENE EDITING-ENCODING THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL GENE EDITING-ENCODING THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL IN VIVO CELL PROGRAMMING THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL IN VIVO CELL PROGRAMMING THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL IN VIVO CELL PROGRAMMING THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL IMMUNE MODULATION THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL IMMUNE MODULATION THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL IMMUNE MODULATION THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL REGENERATIVE AND TISSUE REPAIR THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL REGENERATIVE AND TISSUE REPAIR THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL REGENERATIVE AND TISSUE REPAIR THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL LIPID NANOPARTICLE DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL LIPID NANOPARTICLE DELIVERY SYSTEMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL LIPID NANOPARTICLE DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL POLYMER-BASED DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL POLYMER-BASED DELIVERY SYSTEMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL POLYMER-BASED DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL LIPOPOLYPLEX DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL LIPOPOLYPLEX DELIVERY SYSTEMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL LIPOPOLYPLEX DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL PEPTIDE-BASED DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL PEPTIDE-BASED DELIVERY SYSTEMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL PEPTIDE-BASED DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL VIRAL VECTOR-ASSISTED DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL VIRAL VECTOR-ASSISTED DELIVERY SYSTEMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL VIRAL VECTOR-ASSISTED DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL NAKED MRNA DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL NAKED MRNA DELIVERY SYSTEMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL NAKED MRNA DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY MOLECULE ENCODING TYPE, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL ANTIGEN-ENCODING MRNA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL ANTIGEN-ENCODING MRNA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL ANTIGEN-ENCODING MRNA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL CYTOKINE-ENCODING MRNA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL CYTOKINE-ENCODING MRNA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL CYTOKINE-ENCODING MRNA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL ANTIBODY-ENCODING MRNA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL ANTIBODY-ENCODING MRNA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL ANTIBODY-ENCODING MRNA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL ENZYME-ENCODING MRNA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL ENZYME-ENCODING MRNA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL ENZYME-ENCODING MRNA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL GROWTH FACTOR-ENCODING MRNA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL GROWTH FACTOR-ENCODING MRNA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL GROWTH FACTOR-ENCODING MRNA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL GENE EDITING COMPONENT-ENCODING MRNA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL GENE EDITING COMPONENT-ENCODING MRNA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL GENE EDITING COMPONENT-ENCODING MRNA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY MRNA TYPE, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL CONVENTIONAL NON-REPLICATING MRNA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL CONVENTIONAL NON-REPLICATING MRNA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL CONVENTIONAL NON-REPLICATING MRNA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL SELF-AMPLIFYING MRNA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL SELF-AMPLIFYING MRNA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL SELF-AMPLIFYING MRNA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL CIRCULAR RNA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL CIRCULAR RNA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL CIRCULAR RNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL TRANS-AMPLIFYING MRNA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL TRANS-AMPLIFYING MRNA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL TRANS-AMPLIFYING MRNA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL INTRAMUSCULAR ADMINISTRATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL INTRAMUSCULAR ADMINISTRATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL INTRAMUSCULAR ADMINISTRATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL INTRAVENOUS ADMINISTRATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL INTRAVENOUS ADMINISTRATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL INTRAVENOUS ADMINISTRATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL INTRADERMAL ADMINISTRATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL INTRADERMAL ADMINISTRATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL INTRADERMAL ADMINISTRATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL SUBCUTANEOUS ADMINISTRATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL SUBCUTANEOUS ADMINISTRATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL SUBCUTANEOUS ADMINISTRATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL INTRANASAL ADMINISTRATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL INTRANASAL ADMINISTRATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL INTRANASAL ADMINISTRATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL INTRATUMORAL ADMINISTRATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL INTRATUMORAL ADMINISTRATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL INTRATUMORAL ADMINISTRATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL RARE DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL RARE DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL RARE DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL RESPIRATORY DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL RESPIRATORY DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL RESPIRATORY DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 136. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 137. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 138. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 139. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 141. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 142. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 143. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 144. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 145. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 146. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 147. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 148. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 149. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 150. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 151. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 152. GLOBAL DISCOVERY STAGE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 153. GLOBAL DISCOVERY STAGE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 154. GLOBAL DISCOVERY STAGE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 155. GLOBAL PRECLINICAL STAGE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 156. GLOBAL PRECLINICAL STAGE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 157. GLOBAL PRECLINICAL STAGE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 158. GLOBAL CLINICAL STAGE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 159. GLOBAL CLINICAL STAGE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 160. GLOBAL CLINICAL STAGE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 161. GLOBAL PHASE I MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 162. GLOBAL PHASE I MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 163. GLOBAL PHASE I MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 164. GLOBAL PHASE II MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 165. GLOBAL PHASE II MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 166. GLOBAL PHASE II MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 167. GLOBAL PHASE III MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 168. GLOBAL PHASE III MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 169. GLOBAL PHASE III MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 170. GLOBAL COMMERCIALIZED PRODUCTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 171. GLOBAL COMMERCIALIZED PRODUCTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 172. GLOBAL COMMERCIALIZED PRODUCTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 173. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 174. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 175. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 176. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY PROPHYLACTIC MRNA VACCINES, 2017-2032 (USD MILLION)
TABLE 177. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MRNA MEDICINES, 2017-2032 (USD MILLION)
TABLE 178. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 179. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY MOLECULE ENCODING TYPE, 2017-2032 (USD MILLION)
TABLE 180. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY MRNA TYPE, 2017-2032 (USD MILLION)
TABLE 181. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 182. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 183. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 184. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 185. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 186. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 187. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 188. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY PROPHYLACTIC MRNA VACCINES, 2017-2032 (USD MILLION)
TABLE 189. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MRNA MEDICINES, 2017-2032 (USD MILLION)
TABLE 190. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 191. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY MOLECULE ENCODING TYPE, 2017-2032 (USD MILLION)
TABLE 192. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY MRNA TYPE, 2017-2032 (USD MILLION)
TABLE 193. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 194. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 195. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 196. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 197. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 198. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 199. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 200. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY PROPHYLACTIC MRNA VACCINES, 2017-2032 (USD MILLION)
TABLE 201. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MRNA MEDICINES, 2017-2032 (USD MILLION)
TABLE 202. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 203. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY MOLECULE ENCODING TYPE, 2017-2032 (USD MILLION)
TABLE 204. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY MRNA TYPE, 2017-2032 (USD MILLION)
TABLE 205. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 206. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 207. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 208. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 209. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 210. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 211. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 212. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY PROPHYLACTIC MRNA VACCINES, 2017-2032 (USD MILLION)
TABLE 213. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MRNA MEDICINES, 2017-2032 (USD MILLION)
TABLE 214. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 215. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY MOLECULE ENCODING TYPE, 2017-2032 (USD MILLION)
TABLE 216. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY MRNA TYPE, 2017-2032 (USD MILLION)
TABLE 217. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 218. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 219. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 220. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 221. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 222. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 223. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 224. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY PROPHYLACTIC MRNA VACCINES, 2017-2032 (USD MILLION)
TABLE 225. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MRNA MEDICINES, 2017-2032 (USD MILLION)
TABLE 226. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 227. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY MOLECULE ENCODING TYPE, 2017-2032 (USD MILLION)
TABLE 228. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY MRNA TYPE, 2017-2032 (USD MILLION)
TABLE 229. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 230. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 231. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 232. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 233. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 234. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 235. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 236. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY PROPHYLACTIC MRNA VACCINES, 2017-2032 (USD MILLION)
TABLE 237. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MRNA MEDICINES, 2017-2032 (USD MILLION)
TABLE 238. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 239. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY MOLECULE ENCODING TYPE, 2017-2032 (USD MILLION)
TABLE 240. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY MRNA TYPE, 2017-2032 (USD MILLION)
TABLE 241. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 242. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 243. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 244. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 245. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 246. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 247. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 248. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 249. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY PROPHYLACTIC MRNA VACCINES, 2017-2032 (USD MILLION)
TABLE 250. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MRNA MEDICINES, 2017-2032 (USD MILLION)
TABLE 251. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 252. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY MOLECULE ENCODING TYPE, 2017-2032 (USD MILLION)
TABLE 253. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY MRNA TYPE, 2017-2032 (USD MILLION)
TABLE 254. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 255. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 256. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 257. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 258. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 259. GCC MRNA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 260. GCC MRNA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 261. GCC MRNA THERAPEUTICS MARKET SIZE, BY PROPHYLACTIC MRNA VACCINES, 2017-2032 (USD MILLION)
TABLE 262. GCC MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MRNA MEDICINES, 2017-2032 (USD MILLION)
TABLE 263. GCC MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 264. GCC MRNA THERAPEUTICS MARKET SIZE, BY MOLECULE ENCODING TYPE, 2017-2032 (USD MILLION)
TABLE 265. GCC MRNA THERAPEUTICS MARKET SIZE, BY MRNA TYPE, 2017-2032 (USD MILLION)
TABLE 266. GCC MRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 267. GCC MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 268. GCC MRNA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 269. GCC MRNA THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 270. GCC MRNA THERAPEUTICS MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 271. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 272. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 273. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY PROPHYLACTIC MRNA VACCINES, 2017-2032 (USD MILLION)
TABLE 274. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MRNA MEDICINES, 2017-2032 (USD MILLION)
TABLE 275. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 276. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY MOLECULE ENCODING TYPE, 2017-2032 (USD MILLION)
TABLE 277. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY MRNA TYPE, 2017-2032 (USD MILLION)
TABLE 278. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 279. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 280. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 281. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 282. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 283. BRICS MRNA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 284. BRICS MRNA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 285. BRICS MRNA THERAPEUTICS MARKET SIZE, BY PROPHYLACTIC MRNA VACCINES, 2017-2032 (USD MILLION)
TABLE 286. BRICS MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MRNA MEDICINES, 2017-2032 (USD MILLION)
TABLE 287. BRICS MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 288. BRICS MRNA THERAPEUTICS MARKET SIZE, BY MOLECULE ENCODING TYPE, 2017-2032 (USD MILLION)
TABLE 289. BRICS MRNA THERAPEUTICS MARKET SIZE, BY MRNA TYPE, 2017-2032 (USD MILLION)
TABLE 290. BRICS MRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 291. BRICS MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 292. BRICS MRNA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 293. BRICS MRNA THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 294. BRICS MRNA THERAPEUTICS MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 295. G7 MRNA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 296. G7 MRNA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 297. G7 MRNA THERAPEUTICS MARKET SIZE, BY PROPHYLACTIC MRNA VACCINES, 2017-2032 (USD MILLION)
TABLE 298. G7 MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MRNA MEDICINES, 2017-2032 (USD MILLION)
TABLE 299. G7 MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 300. G7 MRNA THERAPEUTICS MARKET SIZE, BY MOLECULE ENCODING TYPE, 2017-2032 (USD MILLION)
TABLE 301. G7 MRNA THERAPEUTICS MARKET SIZE, BY MRNA TYPE, 2017-2032 (USD MILLION)
TABLE 302. G7 MRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 303. G7 MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 304. G7 MRNA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 305. G7 MRNA THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 306. G7 MRNA THERAPEUTICS MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 307. NATO MRNA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 308. NATO MRNA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 309. NATO MRNA THERAPEUTICS MARKET SIZE, BY PROPHYLACTIC MRNA VACCINES, 2017-2032 (USD MILLION)
TABLE 310. NATO MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MRNA MEDICINES, 2017-2032 (USD MILLION)
TABLE 311. NATO MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 312. NATO MRNA THERAPEUTICS MARKET SIZE, BY MOLECULE ENCODING TYPE, 2017-2032 (USD MILLION)
TABLE 313. NATO MRNA THERAPEUTICS MARKET SIZE, BY MRNA TYPE, 2017-2032 (USD MILLION)
TABLE 314. NATO MRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 315. NATO MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 316. NATO MRNA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 317. NATO MRNA THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 318. NATO MRNA THERAPEUTICS MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 319. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 320. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 321. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 322. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY PROPHYLACTIC MRNA VACCINES, 2017-2032 (USD MILLION)
TABLE 323. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MRNA MEDICINES, 2017-2032 (USD MILLION)
TABLE 324. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 325. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY MOLECULE ENCODING TYPE, 2017-2032 (USD MILLION)
TABLE 326. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY MRNA TYPE, 2017-2032 (USD MILLION)
TABLE 327. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 328. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 329. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 330. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 331. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 332. CANADA MRNA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 333. CANADA MRNA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 334. CANADA MRNA THERAPEUTICS MARKET SIZE, BY PROPHYLACTIC MRNA VACCINES, 2017-2032 (USD MILLION)
TABLE 335. CANADA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MRNA MEDICINES, 2017-2032 (USD MILLION)
TABLE 336. CANADA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 337. CANADA MRNA THERAPEUTICS MARKET SIZE, BY MOLECULE ENCODING TYPE, 2017-2032 (USD MILLION)
TABLE 338. CANADA MRNA THERAPEUTICS MARKET SIZE, BY MRNA TYPE, 2017-2032 (USD MILLION)
TABLE 339. CANADA MRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 340. CANADA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 341. CANADA MRNA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 342. CANADA MRNA THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 343. CANADA MRNA THERAPEUTICS MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 344. MEXICO MRNA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 345. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 346. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY PROPHYLACTIC MRNA VACCINES, 2017-2032 (USD MILLION)
TABLE 347. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MRNA MEDICINES, 2017-2032 (USD MILLION)
TABLE 348. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 349. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY MOLECULE ENCODING TYPE, 2017-2032 (USD MILLION)
TABLE 350. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY MRNA TYPE, 2017-2032 (USD MILLION)
TABLE 351. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 352. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 353. MEXICO MRNA T

Companies Mentioned

  • AbbVie Inc.
  • Abogen Biosciences Co., Ltd.
  • Acuitas Therapeutics Inc.
  • Arcturus Therapeutics Holdings Inc.
  • Beam Therapeutics Inc.
  • BioNTech SE
  • CanSino Biologics Inc.
  • Carisma Therapeutics Inc.
  • Cartesian Therapeutics, Inc.
  • CSL Limited
  • CSPC Pharmaceutical Group Limited
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • Entos Pharmaceuticals Inc.
  • Esperovax, Inc.
  • eTheRNA immunotherapies NV
  • Ethris GmbH
  • GSK plc
  • HDT Bio Corp.
  • Intellia Therapeutics, Inc.
  • Kernal Biologics, Inc.
  • Meiji Holdings Co., Ltd.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Nutcracker Therapeutics, Inc.
  • Pfizer Inc.
  • Providence Therapeutics Holdings Inc.
  • ReCode Therapeutics, Inc.
  • Replicate Bioscience, Inc.
  • Sanofi SA
  • Stemirna Therapeutics Co., Ltd.
  • Strand Therapeutics, Inc.
  • Tessera Therapeutics, Inc.
  • Tiba Biotech LLC
  • Walvax Biotechnology Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages185
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 12.58 Billion
Forecasted Market Value ( USD ) by 2032 $ 27.05 Billion
Compound Annual Growth Rate13.2%
Regions CoveredGlobal
No. of Companies Mentioned35

Related Topics

Related Reports

mRNA Therapeutics - Global Strategic Business Report - Product Image

mRNA Therapeutics - Global Strategic Business Report

  • Report
  • 282 Pages
  • Global
From
mRNA Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

mRNA Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 140 Pages
  • Global
From
mRNA Therapeutics Market by Target Indication (Non-Small Cell Lung Cancer, Melanoma, Muscle-Invasive Urothelial Carcinoma, Propionic Acidemia, and Cystic Fibrosis) and Geographical Regions (North America, Europe, and Asia-Pacific) - Trends and Forecast, Till 2035 - Product Image

mRNA Therapeutics Market by Target Indication (Non-Small Cell Lung Cancer, Melanoma, Muscle-Invasive Urothelial Carcinoma, Propionic Acidemia, and Cystic Fibrosis) and Geographical Regions (North America, Europe, and Asia-Pacific) - Trends and Forecast, Till 2035

  • Report
  • 267 Pages
  • Global
From
Australia mRNA Therapeutics Market: Industry Trends and Global Forecasts, till 2035 - Distribution by Application Area (COVID-19 and Other Indications), and Target Disease Indication (Influenza, Respiratory Syncytial Virus Infection and Cytomegalovirus Diseases) - Product Image

Australia mRNA Therapeutics Market: Industry Trends and Global Forecasts, till 2035 - Distribution by Application Area (COVID-19 and Other Indications), and Target Disease Indication (Influenza, Respiratory Syncytial Virus Infection and Cytomegalovirus Diseases)

  • Report
  • 100 Pages
  • Australia, Global
From
mRNA Therapeutics CDMO Global Market Opportunities and Strategies to 2035 - Product Image

mRNA Therapeutics CDMO Global Market Opportunities and Strategies to 2035

  • Report
  • 358 Pages
  • Global
From

About the mRNA Therapeutics Market

The mRNA Therapeutics market is a subset of the larger Genomics market, which focuses on the development of therapeutics based on messenger RNA (mRNA). mRNA is a type of genetic material that is used to produce proteins in cells. mRNA Therapeutics are designed to target specific diseases by delivering mRNA molecules to cells, which can then be used to produce proteins that can treat or prevent the disease. mRNA Therapeutics have the potential to revolutionize the way diseases are treated, as they can be used to target specific diseases without affecting other parts of the body. The mRNA Therapeutics market is still in its early stages, but is expected to grow rapidly in the coming years. Companies in the market are focused on developing mRNA-based therapeutics for a variety of diseases, including cancer, cardiovascular diseases, and neurological disorders. Some of the companies in the mRNA Therapeutics market include Moderna, CureVac, Arcturus Therapeutics, and BioNTech. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.